Monte Rosa Therapeutics, Inc. (GLUE)
9.31
-1.00
(-9.70%)
USD |
NASDAQ |
Nov 12, 16:00
9.50
+0.19
(+2.04%)
After-Hours: 20:00
Monte Rosa Therapeutics Shareholders Equity (Quarterly) : 496.21M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 496.21M |
| June 30, 2026 | 487.28M |
| March 31, 2026 | 521.92M |
| December 31, 2025 | 233.06M |
| September 30, 2025 | 245.84M |
| June 30, 2025 | 268.08M |
| March 31, 2025 | 275.16M |
| December 31, 2024 | 222.94M |
| September 30, 2024 | 205.46M |
| June 30, 2024 | 224.67M |
| March 31, 2024 | 152.52M |
| December 31, 2023 | 179.25M |
| Date | Value |
|---|---|
| September 30, 2023 | 184.52M |
| June 30, 2023 | 213.65M |
| March 31, 2023 | 243.73M |
| December 31, 2022 | 271.41M |
| September 30, 2022 | 291.09M |
| June 30, 2022 | 302.05M |
| March 31, 2022 | 325.88M |
| December 31, 2021 | 347.52M |
| September 30, 2021 | 369.30M |
| June 30, 2021 | 356.68M |
| March 31, 2021 | -60.62M |
| December 31, 2020 | -48.73M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| United Therapeutics Corp. | 6.276B |
| ACADIA Pharmaceuticals, Inc. | 1.387B |
| Alnylam Pharmaceuticals, Inc. | 3.604B |
| Anika Therapeutics, Inc. | 137.58M |
| Savara, Inc. | 107.85M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 697.72M |
| Total Liabilities (Quarterly) | 201.52M |
| Debt to Equity Ratio | 0.0731 |
| Current Ratio | 10.32 |
| Net Debt Paydown Yield | 0.10% |